<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="81">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01984294</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-337-0133</org_study_id>
    <nct_id>NCT01984294</nct_id>
  </id_info>
  <brief_title>Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin or GS-9669 250 mg or GS-9669 500 mg in Naive or Treatment-Experienced Cirrhotic Subjects With Chronic Genotype 1 HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF)
      fixed-dose combination (FDC) plus ribavirin (RBV) or LDV/SOF plus GS-9669 in treatment-naive
      or treatment-experienced participants with chronic genotype 1 hepatitis C virus (HCV)
      infection. A total of 90 participants are planned to be enrolled in the study for 8 weeks of
      treatment, approximately 60 having had prior treatment with a regimen containing pegylated
      interferon (PEG) and RBV for ≥ 12 weeks. Randomization will be stratified by treatment-naive
      versus treatment-experienced and by HCV genotype (1a versus 1b).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ; ie, 15 IU/mL) 12 weeks following the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Permanently Discontinuing Any Study Drug Due to an Adverse Event</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR24)</measure>
    <time_frame>Posttreatment Weeks 2, 4, 8, and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR2, SVR4, SVR8, and SVR24 was defined as HCV RNA &lt; LLOQ at 2, 4, 8, and 24 weeks following the last dose of study drug, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing On-treatment Virologic Failure</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>On-treatment virologic failure was defined as
Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ while on treatment), or
Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or
Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Viral Relapse</measure>
    <time_frame>Up to Posttreatment Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Viral relapse was defined as having achieved undetectable HCV RNA levels (HCV RNA &lt; LLOQ) at end of treatment, but did not achieve an SVR.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Chronic HCV Infection</condition>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive LDV/SOF plus RBV for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF + GS-9669 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive LDV/SOF plus GS-9669 250 mg for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF + GS-9669 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive LDV/SOF plus GS-9669 500 mg (2 x 250 mg) for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDV/SOF</intervention_name>
    <description>Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily</description>
    <arm_group_label>LDV/SOF+RBV</arm_group_label>
    <arm_group_label>LDV/SOF + GS-9669 250 mg</arm_group_label>
    <arm_group_label>LDV/SOF + GS-9669 500 mg</arm_group_label>
    <other_name>GS-7977/GS-5885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)</description>
    <arm_group_label>LDV/SOF+RBV</arm_group_label>
    <other_name>Ribasphere®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9669</intervention_name>
    <description>GS-9669 tablet(s) administered orally once daily</description>
    <arm_group_label>LDV/SOF + GS-9669 250 mg</arm_group_label>
    <arm_group_label>LDV/SOF + GS-9669 500 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18, with chronic genotype 1 HCV infection

          -  Documented HCV treatment-naïve or treatment-experienced subjects who failed previous
             PEG+RBV regimen

          -  HCV RNA &gt; 10,000 IU/mL at Screening

          -  Presence of compensated cirrhosis

          -  Screening laboratory values within defined thresholds

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner

          -  Co-infection with HIV or hepatitis B virus (HBV)

          -  Current or prior history of clinical hepatic decompensation

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Hyland, DPhil</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 30, 2015</lastchanged_date>
  <firstreceived_date>November 8, 2013</firstreceived_date>
  <firstreceived_results_date>April 30, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV genotype 1</keyword>
  <keyword>HCV</keyword>
  <keyword>Sustained Virologic Response</keyword>
  <keyword>Direct-Acting Antiviral</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>GS-7977</keyword>
  <keyword>GS-5885</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Open Label</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>Treatment-Naive</keyword>
  <keyword>Protease Inhibitors</keyword>
  <keyword>PI</keyword>
  <keyword>Treatment experienced</keyword>
  <keyword>Cirrhotic</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
